CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Standard of care managementWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)

Name (Synonyms) Correlation
drug2089 Reverse transcription polymerase chain reaction Wiki 1.00
drug923 Favipiravir Wiki 0.24

Correlated MeSH Terms (2)

Name (Synonyms) Correlation
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 A Randomised Controlled Trial of Early Intervention in Patients HospItalised With COVID-19: Favipiravir and StaNdard Care vErsEs Standard CaRe

Currently we do not know how best to treat patients infected with COVID-19. This study is looking at whether randomising participants to either favipiravir or to usual care, can help patients with suspected or proven COVID-19 infection.

NCT04373733 Coronavirus Infection Drug: Favipiravir Other: Standard of care management
MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome

Primary Outcomes

Description: Time from randomisation to clinical improvement by two points on a seven-category ordinal scale: Not hospitalised with resumption of normal activities Not hospitalised, but unable to resume normal Hospitalised, not requiring supplemental oxygen Hospitalised, requiring supplemental oxygen Hospitalised, requiring nasal high-flow oxygen therapy, non-invasive mechanical ventilation or both Hospitalised, requiring ECMO (Extra-corporal membrane oxygenation), invasive mechanical ventilation or both Death

Measure: Time to improvement by two points on a seven-category ordinal scale

Time: Up to 28 days from randomisation

Secondary Outcomes

Description: Clinical status of patients at given on the seven-category ordinal scale (see primary endpoint for scale)

Measure: Clinical status on a seven-category ordinal scale (Day 7)

Time: Day 7 from randomisation

Description: Clinical status of patients at given on the seven-category ordinal scale (see primary endpoint for scale)

Measure: Clinical status on a seven-category ordinal scale (Day 14)

Time: Day 14 from randomisation

Description: Survival of patients to end of study

Measure: Overall survival

Time: 28 days from randomisation

Description: Time from randomisation to improvement by two points on the NEWS score of patient condition, if maintained for 24 hours. For details of NEWS score see https://www.rcplondon.ac.uk/projects/outputs/national-early-warning-score-news-2

Measure: Time to improvement by two points on the NEWS score

Time: Up to 28 days from randomisation

Description: Time from randomisation to improvement by two points on the NEWS element score for temperature, if maintained for 24 hours. For details of NEWS score see https://www.rcplondon.ac.uk/projects/outputs/national-early-warning-score-news-2

Measure: Time to improvement by two points on the NEWS element score for temperature

Time: Up to 28 days from randomisation

Description: Time from randomisation to improvement by two points on the NEWS element score for heartrate, if maintained for 24 hours. For details of NEWS score see https://www.rcplondon.ac.uk/projects/outputs/national-early-warning-score-news-2

Measure: Time to improvement by two points on the NEWS element score for heartrate

Time: Up to 28 days from randomisation

Description: Time from randomisation to improvement by two points on the NEWS element score for respiratory rate, if maintained for 24 hours. For details of NEWS score see https://www.rcplondon.ac.uk/projects/outputs/national-early-warning-score-news-2

Measure: Time to improvement by two points on the NEWS element score for respiratory rate

Time: Up to 28 days from randomisation

Description: Time from randomisation to improvement by two points on the NEWS element score for oxygen saturation, if maintained for 24 hours. For details of NEWS score see https://www.rcplondon.ac.uk/projects/outputs/national-early-warning-score-news-2

Measure: Time to improvement by two points on the NEWS element score for oxygen saturation.

Time: Up to 28 days from randomisation

Description: Frequency of admission of patients to intensive care

Measure: Admission to intensive care

Time: Up to 28 days from randomisation

Description: Frequency of requirement to administer mechanical ventilation to patients

Measure: Requirement for mechanical ventilation

Time: Up to 28 days from randomisation

Description: Frequency of requirement to administer non-invasive ventilation, continuous positive airways pressure or high-flow oxygen to patients

Measure: Requirement for non-invasive ventilation, continuous positive airways pressure or high-flow oxygen

Time: Up to 28 days from randomisation

Description: Frequency of culture-confirmed bacterial or fungal infection in patients

Measure: Incidence of bacterial or fungal infection

Time: Up to 28 days from randomisation

Description: Frequency and severity of adverse events in patients not directly attributed by clinicians to COVID-19 infection.

Measure: Incidence of adverse events not directly caused by COVID-19 infection.

Time: Up to 28 days from randomisation.

Other Outcomes

Description: Frequency of readmission to inpatient care of patients discharged from hospital.

Measure: Readmission to inpatient care

Time: Up to 28 days from randomisation

No related HPO nodes (Using clinical trials)